From Investing.com:

InvestingPro is offering Wall Street insights to their subscribers, with discounts up to 50% off for the new year. A 2-year InvestingPro+ subscription with the code SFY24 or a 1-year InvestingPro+ subscription with the code SFY241 comes with an additional 10% off.

Amgen Inc is developing innovative therapies for serious illnesses, with a diverse portfolio focusing on oncology, cardiovascular disease, bone health, neuroscience, nephrology, and inflammation. The company’s assets, including Tarlatamab, AMG-193, BLINCYTO, Xaluritamig, LUMAKRAS, and Bemarituzumab, position it as a leader in immuno-oncology and precision oncology.

Amgen’s Q3 2023 earnings indicate resilience in its base business, with revenues in line with consensus and EPS outperforming expectations. Updated FY23 guidance includes a significant increase in revenue and a slight increase in non-GAAP EPS, reflecting a positive impact from acquisitions and providing clarity on the future pipeline.

The biopharma landscape is intense, with companies like Bristol Myers Squibb competing in the I&I franchise and NSCLC market. Amgen’s strategic focus areas include the obesity program and integration of Horizon’s assets, which have improved the company’s economics.

Challenges for Amgen include concerns about the long-term stability of its revenue due to the decline in its base business and regulatory hurdles, such as the FDA’s Complete Response Letter for Lumakras. However, Amgen has a diversified oncology portfolio and strategic acquisitions that analysts are optimistic will lead to growth.

Amgen faces risks associated with clinical trial outcomes and regulatory approvals, potential underperformance relative to the sector, and erosion of base business revenue if new products and acquisitions do not compensate adequately. Analyst targets range from a price target of $230.00 to $326.00, depending on the firm.

Amgen’s recent acquisitions and focus on innovative therapies could propel it forward, offering a complex picture for investors to consider. The company’s stock has shown low price volatility and consistent increases in dividends, indicating financial stability.

The InvestingPro platform offers subscribers over 10 insightful metrics for Amgen, with a special New Year sale offering up to 50% off the subscription, along with additional discounts using the coupon codes SFY24 or SFY241. For those interested in gaining deeper insights, the InvestingPro subscription offers a comprehensive view of Amgen’s position in the biopharmaceutical industry.



Read more: Wall Street dives into Amgen’s diverse biopharma strategies By Investing.com